Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis.

Authors:
Jung K; Choi S; Song H; Kwak K; Anh S and 6 more

Journal:
Ther Adv Med Oncol

Publication Year: 2023

DOI:
10.1177/17588359231175441

PMCID:
PMC10333643

PMID:
37441327

Journal Information

Full Title: Ther Adv Med Oncol

Abbreviation: Ther Adv Med Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Evidence found in paper:

"This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses and the Meta-analysis of Observational Studies in Epidemiology reporting guidelines., A detailed protocol is registered at the International Prospective Register of Systematic Review (PROSPERO CRD 42021248796)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025